After Cowen & Co. and Chardan Capital gave Dicerna Pharma (NASDAQ: DRNA) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on Dicerna Pharma today and set a price target of $22. The company’s shares closed on Friday at $11.39.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 10.5% and a 39.2% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Dicerna Pharma has an analyst consensus of Strong Buy, with a price target consensus of $22.50, a 97.5% upside from current levels. In a report issued on May 2, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Dicerna Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.61 million. In comparison, last year the company had a GAAP net loss of $15.58 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas.
